Johnson & Johnson (JNJ) Intangibles (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Intangibles came in at $49.1 billion in Q1 2026, up 33.48% year-on-year from $36.8 billion in Q1 2025, and down 2.66% quarter-over-quarter from $50.4 billion in Q4 2025.
Johnson & Johnson (JNJ) Intangibles (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Intangibles across 18 years of filings, most recently posting $49.1 billion for Q1 2026.
- Intangibles for Q1 2026 came in at $49.1 billion, up 33.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.1 billion (up 33.48% YoY), and the FY2025 annual result was $50.4 billion, up 33.99% from the prior year.
- Intangibles came in at $49.1 billion for Q1 2026 at Johnson & Johnson, down from $50.4 billion in the prior quarter.
- In the past five years, Intangibles ranged from a high of $50.4 billion in Q4 2025 to a low of $34.2 billion in Q4 2023.
- The 5-year median for Intangibles is $41.4 billion (2022), against an average of $42.3 billion.
- Across the five-year window, Intangibles decreased 27.74% in 2024 and soared 33.99% in 2025, its largest moves.
- Johnson & Johnson's Intangibles stood at $40.3 billion in 2022, then dropped by 15.27% to $34.2 billion in 2023, then rose by 10.07% to $37.6 billion in 2024, then jumped by 33.99% to $50.4 billion in 2025, then retreated by 2.66% to $49.1 billion in 2026.
- The last three Intangibles figures came in at $49.1 billion (Q1 2026), $50.4 billion (Q4 2025), and $48.7 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 24.45 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.37 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 49.06 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 50.87 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 18.24 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | 10.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 49.06 Bn |
| Dec 28, 2025 | 50.40 Bn |
| Sep 28, 2025 | 48.74 Bn |
| Jun 29, 2025 | 49.84 Bn |
| Mar 30, 2025 | 36.76 Bn |
| Dec 29, 2024 | 37.62 Bn |
| Sep 29, 2024 | 39.49 Bn |
| Jun 30, 2024 | 39.73 Bn |
| Mar 31, 2024 | 34.29 Bn |
| Dec 31, 2023 | 34.18 Bn |
| Oct 1, 2023 | 35.02 Bn |
| Jul 2, 2023 | 46.25 Bn |
| Apr 2, 2023 | 47.45 Bn |
| Jan 1, 2023 | 38.49 Bn |
| Oct 2, 2022 | 40.34 Bn |
| Jul 3, 2022 | 42.41 Bn |
| Apr 3, 2022 | 44.42 Bn |
| Jan 2, 2022 | 46.39 Bn |
| Oct 3, 2021 | 47.78 Bn |
| Jul 4, 2021 | 50.24 Bn |